ライフサイエンスコーパス: alpha-emitter

1 years) resemble closely high-redshift Lyman-alpha emitters.

2 tage of also being able to image beta(-) and alpha emitters.

3 for other high-affinity mAbs and short-lived alpha-emitters.

4 enable tissue- or cell-specific delivery of alpha-emitters.

5 e applied to isolate the residual long-lived alpha-emitters (148)Gd, (154)Dy, and (146)Sm and the bet

6 demonstrated the therapeutic efficacy of the alpha-emitter (149)Tb and beta(-)-emitter (161)Tb.

7 g-lived beta-emitters (129)I, (36)Cl and the alpha-emitters (154)Dy, (148)Gd, (150)Gd, and (146)Sm fr

8 es were dominated by the naturally occurring alpha-emitter (210)Po and that Fukushima-derived doses w

9 The alpha-emitter (211)At deposits a high amount of energy w

10 h the beta-emitters (131)I and (90)Y and the alpha-emitter (211)At in patients with recurrent and new

11 eveloping radiotherapeutics labeled with the alpha-emitter (211)At.

12 emitters (188)Re, (177)Lu, and (90)Y and the alpha-emitters (211)At, (213)Bi, and (212)Pb were compar

13 molecule labeled with the in vivo-generating alpha-emitter (212)Pb, was investigated in a phase 0 tri

14 With the alpha-emitter (213)Bi, significant efficacy was obtained

15 actionated FAPI RPT with the short-half-life alpha-emitter (213)Bi-FAPI-46 is a promising approach th

16 We concluded that alpha-emitter (213)Bi-labeled monoclonal antibody target

17 The alpha-emitter, (213)Bi (T(1/2) = 45.6 min), was conjugat

18 B7 monoclonal antibodies (MAbs) labeled with alpha-emitter 213Bi and Cryptococcus neoformans cells as

19 going targeted radiotherapy or receiving the alpha emitter (223)Ra, which cannot be feasibly imaged c

20 ination with chemotherapy and the use of the alpha emitter (223)Ra-dichloride in prostate cancer, pri

21 tion at DNA scales was also compared with an alpha emitter, (223)Ra.

22 In addition to being the first approved alpha-emitter, (223)RaCl2 is the first radiopharmaceutic

23 cept, DOTAylated-huCC49 was labeled with the alpha-emitter (225)Ac to target tumor-associated glycopr

24 In contrast, the alpha-emitter 225Ac-DOTA-daratumumab had a dose-dependen

25 They comprise the alpha-emitter (227)Th complexed to a 3,2-hydroxypyridino

26 noclonal antibody J591 radiolabeled with the alpha emitter actinium-225.

27 ng noninterventional REASSURE study ((223)Ra alpha-Emitter Agent in Nonintervention Safety Study in m

28 5)Ac in this model suggests a preference for alpha-emitters alone, or possibly in combination, in the

29 ay to develop effective stable chelators for alpha-emitters and are at various stages of development

30 chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recent

31 (223)Ra is an alpha-emitter approved for the treatment of bone metasta

32 These findings suggest that alpha-emitters are highly efficacious in MRD settings, w

33 According to the presented model, alpha-emitters are needed to achieve radiation doses hig

34 alpha-emitters are particularly well adapted to this app

35 exquisitely sensitive to radiation, and the alpha-emitter astatine-211 (211At) deposits prodigious e

36 erapy with an anti-CD45 mAb labeled with the alpha-emitter, astatine-211 ((211)At), as a conditioning

37 ther the short-lived (half-life, 46 minutes) alpha-emitter bismuth 213 ((213)Bi) conjugated to an ant

38 Here, we substituted the alpha-emitter bismuth-213 (213Bi) linked to a monoclonal

39 at pretransplant radioimmunotherapy with the alpha-emitter bismuth-213 (Bi) coupled to anti-CD45 or a

40 Unlike beta particle-emitting isotopes, alpha emitters can selectively kill individual cancer ce

41 This perspective discusses the advantages of alpha-emitter-carrying radiopeptides for the targeted al

42 ode" for TAT to determine whether localizing alpha-emitters closer to the DNA increases their cytotox

43 uding several promising low-energy beta- and alpha-emitters, for radionuclide therapy.

44 sing targeted radiotherapeutics labeled with alpha-emitters have been developed.

45 membrane antigen (PSMA)-targeting beta- and alpha-emitters have been introduced, with promising resp

46 Although alpha-emitters have been studied for many decades, their

47 dium-223 dichloride (radium-223), a targeted alpha-emitter, improved overall survival compared with p

48 There are large amounts of heavy alpha-emitters in nuclear waste and nuclear materials in

49 m is beginning to change in the direction of alpha emitter-labeled analogs, as these demonstrate a co

50 alpha-emitter-labeled anti-CD20 antibodies are promising

51 herapeutics for NHL, although a longer-lived alpha-emitter may be of greater efficacy.

52 For alpha-emitters, microtumors receive high doses (>20 Gy o

53 Alternatively, radioimmunotherapy with alpha-emitters offers the advantage of depositing much h

54 Alpha-particle immunotherapy by targeted alpha-emitters or alpha-emitting isotope generators is a

55 Diffusing alpha-emitter radiation therapy (DaRT), a novel solid tu

56 tential therapeutic efficacy of beta- versus alpha-emitter radioimmunotherapy using radiolabeled DOTA

57 with tracers for imaging and with beta- and alpha-emitter radionuclides for radioimmunotherapy.

58 Alpha-emitter radiopharmaceutical therapy (alpha-RPT) is

59 Alpha-emitter radiopharmaceutical therapy delivers highl

60 We hypothesized the BM-targeting alpha-emitter radium-223 dichloride (Ra223) could target

61 Conclusion: An alpha-emitter's proximity to the DNA yields higher cytot

62 Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with

63 icity from longer path lengths compared with alpha emitters such as (211)At, which has a higher energ

64 mans and showed the benefit of instead using alpha-emitters such as (211)At.

65 Radioimmunotherapy using alpha-emitters such as (213)Bi, (211)At, and (225)Ac has

66 (211)At is an alpha-emitter that may engender less toxicity than other

67 (211)At is among the potential alpha-emitters that are favorable for this concept.

68 are emphasized, and new concepts in targeted alpha-emitter therapy are introduced.

69 Targeted alpha-emitter therapy with isotopes such as (212)Pb has

70 However, the deposition of high-energy alpha-emitters to tumor markers adjacent to a typical le

71 fore, fractionated FAPI RPT with (213)Bi, an alpha-emitter with a half-life of 46 min, appears to be

72 sites, making it an optimal method to target alpha-emitters with short half-lives, such as bismuth-21